FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367182783> ?p ?o ?g. }

• W4367182783 abstract "Abstract Background There is pressing needs to find the biomarker in the selection of neoadjuvant therapy in postmenopausal luminal breast cancer patients. We examined the hypothesis that PIK3CA mutations and low phosphatase and tensin homolog (PTEN) expression affect the response to neoadjuvant therapy and prognosis in postmenopausal luminal breast cancer patients. Methods Postmenopausal patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, up to stage II, who underwent neoadjuvant chemotherapy (NAC; n = 60) or neoadjuvant endocrine therapy (NAE; n = 55) were selected. PIK3CA exon 9 and exon 20 mutations were screened by high resolution melting analysis and confirmed by Sanger sequence. PTEN expression was evaluated by immunohistochemistry. The relationships among PIK3CA mutations, PTEN expression, clinicopathological features, the pathological effect of neoadjuvant therapy, recurrence-free survival (RFS) and overall survival were analyzed. Results Among 115 patients, PIK3CA mutations and low PTEN expression before treatment were detected in 35 patients (30.4%) and in 28 patients (24.3%), respectively. In the NAC group, tumor with PIK3CA mutations showed significantly poorer response than tumor with PIK3CA wild-type ( p = 0.03). On the other hand, in the NAE group, there was no significant difference in pathological therapeutic effect between tumor with PIK3CA mutations and tumor with PIK3CA wild-type ( p = 0.54). In the NAC group, the log-rank test showed no difference in RFS between patients with PIK3CA mutations and PIK3CA wild-type ( p = 0.43), but patients with low PTEN expression showed significantly worse RFS compared to patients with high PTEN expression (5 year RFS 0.64 vs. 0.87, p = 0.01). In the Cox proportional hazards model for RFS, PTEN expression, progesterone receptor, and pathological therapeutic effect were predictive factors for time to recurrence (All p < 0.05). Conclusions PIK3CA mutations are associated with resistance to NAC but do not affect the response to NAE. Low PTEN expression does not affect response to either NAC or NAE but correlates with shorter RFS in patients who received NAC. These biomarkers will be further evaluated for clinical use to treat postmenopausal luminal breast cancer patients." @default.
• W4367182783 created "2023-04-28" @default.
• W4367182783 creator A5003613046 @default.
• W4367182783 creator A5015316489 @default.
• W4367182783 creator A5019622242 @default.
• W4367182783 creator A5022393845 @default.
• W4367182783 creator A5027749039 @default.
• W4367182783 creator A5029247118 @default.
• W4367182783 creator A5032391627 @default.
• W4367182783 creator A5043769248 @default.
• W4367182783 creator A5050118531 @default.
• W4367182783 creator A5051131902 @default.
• W4367182783 creator A5056390161 @default.
• W4367182783 creator A5057314745 @default.
• W4367182783 creator A5065280788 @default.
• W4367182783 creator A5078301182 @default.
• W4367182783 creator A5087402935 @default.
• W4367182783 date "2023-04-27" @default.
• W4367182783 modified "2023-10-15" @default.
• W4367182783 title "The impact of PIK3CA mutations and PTEN expression on the effect of neoadjuvant therapy for postmenopausal luminal breast cancer patients" @default.
• W4367182783 cites W1963704957 @default.
• W4367182783 cites W1979946545 @default.
• W4367182783 cites W1994703138 @default.
• W4367182783 cites W2013956549 @default.
• W4367182783 cites W2027735722 @default.
• W4367182783 cites W2029147710 @default.
• W4367182783 cites W2029461564 @default.
• W4367182783 cites W2040384408 @default.
• W4367182783 cites W2044702943 @default.
• W4367182783 cites W2050580690 @default.
• W4367182783 cites W2061066030 @default.
• W4367182783 cites W2089123024 @default.
• W4367182783 cites W2096283457 @default.
• W4367182783 cites W2105895425 @default.
• W4367182783 cites W2117357260 @default.
• W4367182783 cites W2132619562 @default.
• W4367182783 cites W2137853125 @default.
• W4367182783 cites W2139248078 @default.
• W4367182783 cites W2144957807 @default.
• W4367182783 cites W2147415463 @default.
• W4367182783 cites W2160043536 @default.
• W4367182783 cites W2170872221 @default.
• W4367182783 cites W2295277526 @default.
• W4367182783 cites W2392504248 @default.
• W4367182783 cites W2517421365 @default.
• W4367182783 cites W2560367415 @default.
• W4367182783 cites W2587365770 @default.
• W4367182783 cites W2597420951 @default.
• W4367182783 cites W2728962997 @default.
• W4367182783 cites W2767814595 @default.
• W4367182783 cites W2789428140 @default.
• W4367182783 cites W3122861570 @default.
• W4367182783 doi "https://doi.org/10.1186/s12885-023-10853-y" @default.
• W4367182783 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37106324" @default.
• W4367182783 hasPublicationYear "2023" @default.
• W4367182783 type Work @default.
• W4367182783 citedByCount "0" @default.
• W4367182783 crossrefType "journal-article" @default.
• W4367182783 hasAuthorship W4367182783A5003613046 @default.
• W4367182783 hasAuthorship W4367182783A5015316489 @default.
• W4367182783 hasAuthorship W4367182783A5019622242 @default.
• W4367182783 hasAuthorship W4367182783A5022393845 @default.
• W4367182783 hasAuthorship W4367182783A5027749039 @default.
• W4367182783 hasAuthorship W4367182783A5029247118 @default.
• W4367182783 hasAuthorship W4367182783A5032391627 @default.
• W4367182783 hasAuthorship W4367182783A5043769248 @default.
• W4367182783 hasAuthorship W4367182783A5050118531 @default.
• W4367182783 hasAuthorship W4367182783A5051131902 @default.
• W4367182783 hasAuthorship W4367182783A5056390161 @default.
• W4367182783 hasAuthorship W4367182783A5057314745 @default.
• W4367182783 hasAuthorship W4367182783A5065280788 @default.
• W4367182783 hasAuthorship W4367182783A5078301182 @default.
• W4367182783 hasAuthorship W4367182783A5087402935 @default.
• W4367182783 hasBestOaLocation W43671827831 @default.
• W4367182783 hasConcept C121608353 @default.
• W4367182783 hasConcept C126322002 @default.
• W4367182783 hasConcept C143998085 @default.
• W4367182783 hasConcept C204232928 @default.
• W4367182783 hasConcept C2777609662 @default.
• W4367182783 hasConcept C2778292576 @default.
• W4367182783 hasConcept C2779549131 @default.
• W4367182783 hasConcept C2780140570 @default.
• W4367182783 hasConcept C2781197716 @default.
• W4367182783 hasConcept C502942594 @default.
• W4367182783 hasConcept C530470458 @default.
• W4367182783 hasConcept C55493867 @default.
• W4367182783 hasConcept C62478195 @default.
• W4367182783 hasConcept C71924100 @default.
• W4367182783 hasConcept C84606932 @default.
• W4367182783 hasConcept C86554907 @default.
• W4367182783 hasConcept C86803240 @default.
• W4367182783 hasConceptScore W4367182783C121608353 @default.
• W4367182783 hasConceptScore W4367182783C126322002 @default.
• W4367182783 hasConceptScore W4367182783C143998085 @default.
• W4367182783 hasConceptScore W4367182783C204232928 @default.
• W4367182783 hasConceptScore W4367182783C2777609662 @default.
• W4367182783 hasConceptScore W4367182783C2778292576 @default.
• W4367182783 hasConceptScore W4367182783C2779549131 @default.
• W4367182783 hasConceptScore W4367182783C2780140570 @default.
• W4367182783 hasConceptScore W4367182783C2781197716 @default.

• next